Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6113560 | Critical Reviews in Oncology/Hematology | 2016 | 46 Pages |
Abstract
Acute lymphoblastic leukemia (ALL) is a clonal disease characterized by B or T lineage. Here we cover the clinical manifestations, pathophysiology and therapy for ALL. Additionally, we will discuss the evidence for minimal residual disease assessment, novel molecular targets and newly developed targeted therapies. The separation of ALL into Philadelphia chromosome positive and recently into Philadelphia-like disease represents the most exciting developments in this disease. Finally, the advent of new immunotherapeutic approaches led us to predict that in few years, ALL therapy might be based heavily on non-chemotherapeutic approaches.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Omar Al Ustwani, Neha Gupta, Hatoon Bakhribah, Elizabeth Griffiths, Eunice Wang, Meir Wetzler,